Everolimus in Breast Cancer Patients After Pre-operative Chemotherapy

A Randomized Study of mTOR Inhibition by RAD001 (Everolimus) in Invasive Breast Cancer Patients After Pre-operative Use of Anthracycline and/or Taxane-based Chemotherapy

Status

UNKNOWN

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01088893

Enrollment

Registered

2010-03-17

Start date

2009-11-30

Completion date

2013-03-31

Last updated

2012-05-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Neoplasms

Keywords

everolimus, neoadjuvant, m-TOR inhibitor

Brief summary

This is a randomized controlled pilot study investigating signals involved in drug resistance to chemotherapy. Patient will be randomized to undergo observation or to receive Everolimus after completion of neoadjvuant treatment (anthracycline and/or taxane-based) and before surgery. The patients will be monitored for efficacy and safety.

Interventions

DRUGEverolimus

10mg/d) for three weeks 1 week after completion of neoadjvuant treatment and before surgery

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

FEMALE

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Women aged ≥ 18 years; * Histologically and/or cytologically confirmed invasive ductal or lobular breast cancer; * Tumor of 3 cm or greater at time of diagnosis * Measurable primary tumor after neoadjuvant treatment before randomization * No prior chemotherapy for breast cancer; * ECOG performance status ≤1 or Karnofsky performace status ≥ 70% * Adequate liver/renal function * Able to swallow whole tablets. * Able to give written informed consent * Able to follow prescription instructions reasonably well

Exclusion criteria

* Male patient * Prior history of other malignancy within 5 years of study entry, aside from contralateral breast carcinoma, appropriately treated cervical carcinoma in situ, or adequately treated basal or squamous cell carcinoma of the skin * Distant metastasis, including skin involvement beyond the breast area * Other severe acute or chronic medical or psychiatric condition, or laboratory abnormality that would impart, in the judgment of the investigator, excess risk associated with study participation or study drug administration, or which, in the judgment of the investigator, would make the patient inappropriate for entry into this study

Design outcomes

Primary

Measure	Time frame
measure change of biomarkers in pre- and post- surgery samples	baseline and 1 month

Countries

China

Contacts

Primary ContactLouis Chow, MD

(852)28610286

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 1, 2026